Laserfiche WebLink
..i <br /> State of California-Health and Welfare Agency <br /> Department of Health Services <br /> Page 6 of 8 pages <br /> RADIOACTIVE MATERIAL LICENSE License Number: 1276-39 <br /> Supplementary Sheet Amendment Number: 59 <br /> 18. Records of leak test results shall be kept in units of microcuries and maintained for inspection. Records may <br /> be disposed of following Department inspection. Any leak test revealing the presence of 0.005 microcuries <br /> or more of removable radioactive material shall be reported to the Department of Health Services, Radiologic <br /> Health Branch, 601 N. 7th Street P.O. Box 942732, Sacramento, CA 94234-7320, within five days of the test. <br /> This report shall include a description of the defective source or device, the results of the test, and the <br /> corrective action taken. <br /> 19. Any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less <br /> of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material. <br /> 20. Except for alpha sources, the periodic leak test required by Condition 15 does not apply to sealed sources <br /> that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to <br /> any use or transfer to another person unless they have been leak tested within six months prior to the date <br /> of use or transfer. <br /> 21. The licensee shall conducf'a physical inventory every six months to account for all sealed sources and/or <br /> devices received and-possessed under the license. Records of the inventories shall be maintained for <br /> inspection, and may be disposed of following Department inspection. <br /> 22. Treatment and management of patients receiving therapeutic quantities of unsealed radioactive materials shall <br /> be in accordance with guidance contained in Chapter 4, 'Release from Hospital of Patients Containing <br /> Radioactive Material' National Council on Radiation Protection and Measurements(NCRP) Report No. 37, <br /> "Precautions in the Management of Patients Who Have Received Therapeutic Amounts of Radionuclides" <br /> (NCRP Publications, P. O. Box 30175, Washington, D. C., 20014). <br /> 23. Treatment and management of patients undergoing brachytherapy shall be in accordance with guidance <br /> contained in Chapter 5, "Safety Precautions in Clinical Application", National Council on Radiation <br /> Protection and Measurements (NCRP) Report No. 40, Protection Against Radiation From Brachytherapy <br /> Sources (NCRP Publications, P. O. Box 30175, Washington, D.C., 20014). <br /> 24. Notwithstanding the six-month test interval requirement of Section 30275 of the California Radiation Control <br /> Regulations,medical cesium-137 sources(3M Company Models 6500-6507 or old Model 6D6C,and Isotope <br /> Products Model 67-800 or 67-820 series) possessed under this license may be tested for leakage and/or <br /> contamination at three-year intervals. <br /> 25. Except as otherwise specifically provided by this license, radiopharmaceuticals to be administered to humans <br /> shall be procured in prepackaged, precalibrated form from a supplier who is registered with the U. S. Food <br /> and Drug Administration, or prepared and compounded, from a prescription, in accordance with the <br /> regulations of the California Board of Pharmacy. <br /> 26. Except as otherwise specifically provided by this license, radioactive biologicals (including human serum <br /> albumin)to be administered to humans shall be procured in prepackaged, precalibrated form from a supplier <br /> who is licensed for the preparation and distribution of such products by the Division of Biologies Standards <br /> of the National Institutes of Health, or U. S. Food and Drug Administration; or prepared in accordance with <br /> the regulations of the California Board of Pharmacy. <br />